[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100489246":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":66,"collaborators":10,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":10,"maxAge":10,"enrollmentInfo":78,"targetDuration":10,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University of Michigan","OTHER",[8,15,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Enrolled participants prior to transplant",null,"Participants will be consented.",[13,14],"Other: Biospecimen collection","Other: Data collection",{"label":16,"type":10,"description":11,"interventionNames":17},"Enrolled participant after transplant",[13,14],{"label":19,"type":10,"description":20,"interventionNames":21},"Retrospective participant data","Waiver of consent for secondary use of existing data.",[14],[23,27],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Biospecimen collection","Specimens that may be collected include urine, blood, saliva, kidney tissue, etc. Biospecimens will be collected to establish the RESOLVE biobank.",[16,9],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"Data collection","Data collection for all groups",[16,9,19],[32],{"name":33,"affiliation":5,"role":34},"Eloise Salmon, MD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"Ashley Rahimi","CONTACT","734-647-5446","asboggs@med.umich.edu",{"name":33,"role":38,"phone":42,"phoneExt":10,"email":43},"734-936-4210","salmonel@med.umich.edu",[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Ann Arbor","Michigan","48109","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-83.74088,42.27756,{"lat":56,"lon":55},[59,62,63],{"name":10,"role":38,"phone":60,"phoneExt":10,"email":61},"734-232-4830","umkidneystudies@umich.edu",{"name":33,"role":34,"phone":10,"phoneExt":10,"email":10},{"name":64,"role":65,"phone":10,"phoneExt":10,"email":10},"Debbie Gipson, MD","SUB_INVESTIGATOR",{"type":34,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Eloise Salmon","Assistant Professor of Pediatrics","100489246","recurrence-post-transplant-observational-study-in-focal-segmental-glomerulosclerosis-and-minimal-change-disease-100489246",false,"NCT05650619","Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease","Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis (FSGS) and Minimal Change Disease (MCD)","RESOLVE","Inclusion Criteria:\n\n* Retrospective non-consented participant group had a transplant from the year 2000 and onward.\n* Diagnosis of FSGS or MCD in the native kidney (prior to transplant).\n\nExclusion Criteria:\n\n* Pathologic diagnosis other than FSGS or MCD\n* FSGS or MCD secondary to a known disorder (e.g. lupus nephritis, Immunoglobulin A (IgA) nephropathy, malignancy)","ALL",{"count":79,"type":80},300,"ESTIMATED","OBSERVATIONAL","The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and mortality. Efforts to understand its mechanisms and improve its treatment have been limited by small sample sizes in single center studies and misclassification in registry studies. Recent advances in the understanding of the mechanisms of FSGS in the native kidney has reinvigorated the scientific community to develop a collaborative community to advance research into the epidemiology, mechanisms, interventions, and outcomes.\n\nThe purpose of RESOLVE is to gather a group of people with FSGS and MCD that have had or will have a kidney transplant to create a bank of information and biospecimens so researchers can more effectively study these diseases.",[84,85,86,87],"Focal Segmental Glomerulosclerosis","Minimal Change Disease","FSGS","MCD",[89,90,91,92,93],"Kidney disease","Kidney transplant","Adult","Children","Recurrence","2026-04-23",{"date":96,"type":97},"2026-04-29","ACTUAL",{"date":99,"type":97},"2022-12-08",{"date":101,"type":80},"2027-12",{"name":5,"class":6},1]